BioSpace reviewed the third-quarter 2020 financial announcements from some of the biopharma industry’s leading players.
W2O reported 2019 revenue increased by 26 percent to $223 million from $177 million in 2018 and improved operating profit.
Teva Pharmaceutical’s deutetrabenazine for the treatment of tics in pediatric patients with moderate to severe Tourette Syndrome did not meet the primary endpoint in the Phase II/III ARTISTS 1 and Phase III ARTISTS 2 trials.
Teva Pharmaceutical Industries said a two-year restructuring enabled the world’s largest generic drugmaker to turn a corner, as the company reported slightly better than expected fourth-quarter 2019 results.
Biogen reported full-year 2019 financial results, citing total revenues of $14.378 billion, an increase of 7% from the previous year.
Eli Lilly’s stock prices ticked up following the company’s announcement of strong quarterly sales and positive Phase III results in severe atopic dermatitis.
Swiss pharma giant Novartis is writing off the company’s program to develop a generic copy of GlaxoSmithKline’s blockbuster inhaler Advair.
AbbVie’s third-quarter 2019 global net revenue totaled nearly $8.48 billion, an increase of 3.0 percent on a reported basis (3.5 percent operationally).
Novo Nordisk’s sales forecast for 2019 was raised due to growing demand for obesity products and a new injectable treatment for diabetes, which is now the company’s growth engine as insulin sales decline.
Teva Pharmaceutical Industries reported a smaller-than-expected drop in second-quarter 2019 profit and said the chief financial officer was leaving the company.